Amazon Bio Discovery

Recursion is a TechBio company focused on transforming drug discovery by combining biology, data, and artificial intelligence. Founded over a decade ago, the company pioneered the use of large-scale cellular imaging to train AI models that decode the biological drivers of disease. Recursion’s mission is to deliver better medicines through novel insights and precision design, reducing the high failure rates of traditional drug development. Its proprietary Recursion OS platform integrates massive biological datasets with machine learning to accelerate discovery from target identification to clinical development. The company has built an advanced pipeline of potential first-in-class and best-in-class therapies targeting aggressive cancers and rare diseases. Automated wet labs and robotics enable millions of experiments per week, feeding continuous learning into its AI models.

Genedata Biologics® streamlines discovery of biotherapeutics including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs. The most widely adopted platform across the industry, it integrates all discovery workflows so you can focus on true innovation. Accelerate research with a first-in-class platform uniquely designed from the start to digitalize biotherapeutic discovery. The platform facilitates complex R&D processes by designing, tracking, testing, and assessing novel biotherapeutics drugs. It works with any format, from antibodies, bi- or multi-specifics, ADCs, novel scaffolds, and therapeutic proteins, to engineered therapeutic cell lines such as TCRs and CAR-T cells. Acting as a central end-to-end data backbone, Genedata Biologics integrates all R&D processes, from library design and immunizations, selections and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, to candidate developability and manufacturability assessments.